Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up – Still a Buy?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares gapped up prior to trading on Tuesday . The stock had previously closed at $7.65, but opened at $8.10. Telix Pharmaceuticals shares last traded at $8.3260, with a volume of 104,984 shares changing hands.

Analyst Ratings Changes

TLX has been the subject of several recent analyst reports. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday. Canaccord Genuity Group upgraded Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Performance

The company has a fifty day moving average price of $8.41 and a 200-day moving average price of $10.22.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds have recently bought and sold shares of TLX. Rhumbline Advisers increased its position in Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the period. IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at approximately $213,000. Blair William & Co. IL acquired a new position in shares of Telix Pharmaceuticals in the 2nd quarter worth approximately $217,000. JPMorgan Chase & Co. acquired a new stake in Telix Pharmaceuticals in the 3rd quarter valued at $243,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter valued at $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.